Marksans Pharma acquires US-based Co Time-Cap

Marksans Pharma through its subsidiary acquired the company.

Marksans Pharma Limited has, through its wholly owned subsidiary, MarksansPharma lnc., acquired 100% of the outstanding shares of Time-Cap Laboratories, Inc., a New York corporation having its principal office at 7 Michael Avenue, Farmingdale, New York.

• Kev Highlights
• Time-Cap has a US FDA-approved manufacturing facility in Farmingdale, New York.
• It has an experienced research and development team which over the years has optimized its production processes and introduced a number of new products.
• Time-Cap has developed differentiating manufacturing expertjse, resulting in a key competitive advantage in the market place for extended and delayed-release prod ucts, and coating services.
• The company has substantial growth opportunities with a robust new product line in the pipeline. Its capabilities with respect to extended-release products offer opportunities to pursue ANDA s for high margin products.
• Time-Cap has an expert management team comprised of industry pioneers with deep expertise, as well as a loyal and technically sophisticated employee base.

 
With its acquisition of Time-Cap, Marksans is strategically increasing its presence in the US market, which is the largestpharmaceutical market in the world. This transaction will be EPS accretive.
 
On this occasion, Mark Saldanha, Managing Director and CEO of Marksans Pharma Limited, offered the following remarks: "Time-Cap offers Marksans an ideal platfonn to expand its operation in the US. Thjs strategic acquisition helps Marksans to expand its manufacturing capabilities along with product portfolio and penetration into the US"